Trial reportDrug design, development and therapy2026
Glycopyrronium Bromide versus Droperidol for Prophylaxis of Postoperative Nausea and Vomiting in Hysteroscopic Day Surgery: A Randomized, Double-Blind, Non-Inferiority Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the efficacy of glycopyrronium bromide in preventing postoperative nausea and vomiting (PONV) in patients undergoing gynecological hysteroscopic day surgery. Patients and Methods: This study is a prospective, randomized, double-blind, non-inferiority trial. The non-inferiority margin was set at 15%. Patients scheduled for elective gynecological hysteroscopic day surgery under general anesthesia from November 2025 to February 2026 were selected. A total of 260 eligible patients were randomly assigned to receive glycopyrronium bromide (Group G) or droperidol (Group F). Patients in Group G received intravenous glycopyrronium bromide 0.2 mg, while those in Group F received intravenous droperidol 1 mg. Surgery was performed under general anesthesia with remimazolam combined with alfentanil. The primary outcome observed was the incidence of PONV within 24 hours after surgery in both groups. Results: Within 24 hours postoperatively, the incidence of nausea and vomiting in Group G was non-inferior to that in Group F (37.1% vs 34.1%, risk difference 3.0%; 95% confidence interval -9.0 to 14.7; upper limit < non-inferiority margin of 15%). In the PACU, the incidence of nausea and vomiting in Group G and Group F was 22.6% vs 17.9%, respectively (risk difference 4.7%; 95% confidence interval -5.4 to 14.6). Regarding perioperative adverse reactions, there was no statistically significant difference in the incidence of hypotension between the two groups(30.6% vs 39.8%, P=0.130). The incidence of bradycardia was higher in Group F than in Group G (7.3% vs 1.6%, P=0.030). Furthermore, the incidence of parched mouth was higher in Group G than in Group F (67.7% vs 15.4%, P=0.001). Conclusion: This study found that glycopyrronium bromide is non-inferior to droperidol in preventing PONV within 24 hours after gynecological hysteroscopic day surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.